MDxHealth SA (MDXH)
(Delayed Data from NSDQ)
$2.07 USD
+0.07 (3.50%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $2.11 +0.04 (1.93%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.07 USD
+0.07 (3.50%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $2.11 +0.04 (1.93%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum C VGM
Zacks News
Agiliti (AGTI) Q4 Earnings Beat Estimates
by Zacks Equity Research
Agiliti (AGTI) delivered earnings and revenue surprises of 8.33% and 0%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -3.70% and 3.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Beats Q3 Earnings Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 5.41% and 1.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Soars 9.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Surgery Partners (SGRY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Pediatrix Medical Group (MD) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -25.58% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MDxHealth SA Sponsored ADR (MDXH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
MDxHealth SA Sponsored ADR (MDXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MDxHealth SA Sponsored ADR (MDXH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MDxHealth SA Sponsored ADR (MDXH) delivered earnings and revenue surprises of 6.25% and 10.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cano Health, Inc. (CANO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cano Health, Inc. (CANO) delivered earnings and revenue surprises of -211.11% and 8.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
AMN Healthcare Services (AMN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 10.70% and 0.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MDxHealth SA Sponsored ADR (MDXH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MDxHealth SA Sponsored ADR (MDXH) delivered earnings and revenue surprises of 87.50% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) Q1 Earnings Surpass Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 2.02% and 1.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AMN Healthcare Services (AMN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 5.51% and 1.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Premier, Inc. (PINC) Q3 Earnings Match Estimates
by Zacks Equity Research
Premier, Inc. (PINC) delivered earnings and revenue surprises of 0% and 8.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: MDxHealth SA Sponsored ADR (MDXH) Q1 Earnings Expected to Decline
by Zacks Equity Research
MDxHealth SA Sponsored ADR (MDXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance (ELV) to Divest Life & Disability Business to StanCorp
by Zacks Equity Research
With the sale of the life and disability business, Elevance Health (ELV) is focusing on growing its more profitable operations.
Is a Surprise Coming for MDxHealth (MDXH) This Earnings Season?
by Zacks Equity Research
MDxHealth (MDXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.